
|Articles|May 8, 2008
Stiefel Laboratories acquires ABR Invent and ABR Development
Coral Gables, Fla. - Stiefel Laboratories announces the acquisition of ABR Invent and ABR Development, developers of the dermal filler Atlean, PRNewswire reports.
Advertisement
Coral Gables, Fla.
- Stiefel Laboratories announces the acquisition of ABR Invent and ABR Development, developers of the dermal filler Atlean, PRNewswire reports.
Stiefel will acquire all shares of ABR Invent and ABR Development through a definitive stock purchase agreement. Both Invent and Development are based in France.
Atlean(R) is a bio-resorbable, sculpting and modeling dermal filler with hyaluronic acid and tricalcium phosphate particles. Atlean(R) received a CE-Mark granted in 2006 and is marketed in France and Italy, according to PRNewswire.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Envudeucitinib Achieves 54% PASI 100 Rate at 48 Weeks in Phase 3 Extension
2
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
3
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
4
Biologic Therapies in AD and CSU: Progress and the Push for Precision Medicine
5











